X

Trial Profile

A Phase 1 Study of WU-NK-101 in Patients With Relapsed or Refractory (R/R) Acute Myeloid Leukemia (AML)

Status: Active, no longer recruiting

Phase of Trial: Phase I

Latest Information Update: 07 Feb 2025

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs WU NK 101 (Primary) ; Cyclophosphamide; Fludarabine
Indications Acute myeloid leukaemia
Focus Adverse reactions; First in man
Sponsors WUGEN

Most Recent Events

10 Dec 2024 Results presented at the 66th American Society of Hematology Annual Meeting and Exposition
05 Dec 2024 According to a Wugen media release, company to present data from this study in a poster presentation at the American Society of Hematology (ASH) Annual Meeting & Exposition, Dec. 7-10 in San Diego.
22 Nov 2024 Planned End Date changed from 31 Dec 2025 to 31 Jan 2025.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com